Treatment of Headache Following Triptan Failure After Successful Triptan Therapy

Marc E Lenaerts, James R. Couch

Research output: Contribution to journalArticle

Abstract

Triptans should remain the first choice in migraine abortive treatment. They are not always effective or adequate for specific patients. Before declaring a triptan in appropriate for a given patient, the provider ought to be analytical about the rationale and especially the use of objective efficacy outcome measures and ensure that treatment is prescribed and used appropriately. Other ergot derivatives, especially dihydroergotamine, may on one hand share common contraindications of triptans but on the other hand can be quite effective where triptans failed. Non-steroids are simple, readily available, and overall safe, and evidence for their efficacy in migraine is plentiful. Opioid analgesics are blatantly overprescribed especially in non-complicated migraine patients. These should be used with great care and restraint and closely monitored. Frequent opioid usage often leads to tolerance, dependence, and medication overuse headache. Neurostimulation is gaining momentum in the armamentarium of migraine management but at the present time remains primarily focused on prophylaxis, yet abortive use is expected to grow.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Treatment Options in Neurology
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Tryptamines
Migraine Disorders
Headache
Opioid Analgesics
Secondary Headache Disorders
Dihydroergotamine
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • Ergot derivatives
  • Headache
  • Neurostimulation
  • Non-steroids
  • Opioid analgesics
  • Triptan Failure
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment of Headache Following Triptan Failure After Successful Triptan Therapy. / Lenaerts, Marc E; Couch, James R.

In: Current Treatment Options in Neurology, Vol. 17, No. 6, 01.06.2015, p. 1-7.

Research output: Contribution to journalArticle

@article{bb3f440f16244b86b34302a85f958b3c,
title = "Treatment of Headache Following Triptan Failure After Successful Triptan Therapy",
abstract = "Triptans should remain the first choice in migraine abortive treatment. They are not always effective or adequate for specific patients. Before declaring a triptan in appropriate for a given patient, the provider ought to be analytical about the rationale and especially the use of objective efficacy outcome measures and ensure that treatment is prescribed and used appropriately. Other ergot derivatives, especially dihydroergotamine, may on one hand share common contraindications of triptans but on the other hand can be quite effective where triptans failed. Non-steroids are simple, readily available, and overall safe, and evidence for their efficacy in migraine is plentiful. Opioid analgesics are blatantly overprescribed especially in non-complicated migraine patients. These should be used with great care and restraint and closely monitored. Frequent opioid usage often leads to tolerance, dependence, and medication overuse headache. Neurostimulation is gaining momentum in the armamentarium of migraine management but at the present time remains primarily focused on prophylaxis, yet abortive use is expected to grow.",
keywords = "Ergot derivatives, Headache, Neurostimulation, Non-steroids, Opioid analgesics, Triptan Failure, Triptans",
author = "Lenaerts, {Marc E} and Couch, {James R.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s11940-015-0353-6",
language = "English (US)",
volume = "17",
pages = "1--7",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of Headache Following Triptan Failure After Successful Triptan Therapy

AU - Lenaerts, Marc E

AU - Couch, James R.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Triptans should remain the first choice in migraine abortive treatment. They are not always effective or adequate for specific patients. Before declaring a triptan in appropriate for a given patient, the provider ought to be analytical about the rationale and especially the use of objective efficacy outcome measures and ensure that treatment is prescribed and used appropriately. Other ergot derivatives, especially dihydroergotamine, may on one hand share common contraindications of triptans but on the other hand can be quite effective where triptans failed. Non-steroids are simple, readily available, and overall safe, and evidence for their efficacy in migraine is plentiful. Opioid analgesics are blatantly overprescribed especially in non-complicated migraine patients. These should be used with great care and restraint and closely monitored. Frequent opioid usage often leads to tolerance, dependence, and medication overuse headache. Neurostimulation is gaining momentum in the armamentarium of migraine management but at the present time remains primarily focused on prophylaxis, yet abortive use is expected to grow.

AB - Triptans should remain the first choice in migraine abortive treatment. They are not always effective or adequate for specific patients. Before declaring a triptan in appropriate for a given patient, the provider ought to be analytical about the rationale and especially the use of objective efficacy outcome measures and ensure that treatment is prescribed and used appropriately. Other ergot derivatives, especially dihydroergotamine, may on one hand share common contraindications of triptans but on the other hand can be quite effective where triptans failed. Non-steroids are simple, readily available, and overall safe, and evidence for their efficacy in migraine is plentiful. Opioid analgesics are blatantly overprescribed especially in non-complicated migraine patients. These should be used with great care and restraint and closely monitored. Frequent opioid usage often leads to tolerance, dependence, and medication overuse headache. Neurostimulation is gaining momentum in the armamentarium of migraine management but at the present time remains primarily focused on prophylaxis, yet abortive use is expected to grow.

KW - Ergot derivatives

KW - Headache

KW - Neurostimulation

KW - Non-steroids

KW - Opioid analgesics

KW - Triptan Failure

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=84929085990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929085990&partnerID=8YFLogxK

U2 - 10.1007/s11940-015-0353-6

DO - 10.1007/s11940-015-0353-6

M3 - Article

VL - 17

SP - 1

EP - 7

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 6

ER -